<DOC>
	<DOCNO>NCT02685111</DOCNO>
	<brief_summary>To compare efficacy safety Day 2 ( D2 ) cycle pegfilgrastim Intermittent Every Other Days 5 Shot ( D3-11 ) filgrastim early breast cancer patient treat adjuvant Docetaxel , Doxorubicin , Cyclophosphamide ( TAC ) regimen</brief_summary>
	<brief_title>Intermittent G-CSF Patients With Breast Cancer Receiving Adjuvant Docetaxel , Doxorubicin , Cyclophosphamide ( TAC )</brief_title>
	<detailed_description>According manufacturer ' recommendation ( Amgen : Neupogenᵀᴹ ) , filgrastim start 24 hr last dose chemotherapy continue absolute neutrophil count ( ANC ) recover within normal range ( 14 day ) . However , economic practical reason and/or patient 's convenience , common practice initiate filgrastim later day cycle and/or administer short course treatment . Data several clinical study show 10-11 day ' filgrastim treatment require optimal prophylaxis febrile neutropenia ( FN ) , data cancer show suboptimal use G-CSFs could deteriorate clinical outcome . However , two recent randomize study breast cancer patient undergo TAC chemotherapy , acceptable incidence ( 7-18 % ) FN show consecutive 6 7-daily filgrastim scheme . Also , although theoretical concern wide fluctuation patient 's ANC time alternate intermittent filgrastim administration , difference clinical outcome daily- intermittent-dose filgrastim schedule previous literature , intermittent every day 5 shot-filgrastim scheme would clinical outcome comparable previous consecutive 6 7-daily filgrastim scheme coverage ANC nadir . Therefore , justified investigate non-inferiority intermittent every day 5 shot-filgrastim scheme compare control arm use pegfilgrastim D2 .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Febrile Neutropenia</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>The patient underwent surgery pathologically diagnose early breast cancer ( high risk stage II stage III ) completely resect stage IV , anticipate undergo adjuvant chemotherapy TAC regimen ( docetaxel , doxorubicin , cyclophosphamide ) The patient satisfy laboratory finding enrollment clinical trial : A . Absolute Neutrophil Count ( ANC ) ≥ 1,500/mm³ ; B. Platelet Count ≥ 100,000/mm³ ; C. Adequate renal function ( Cr &lt; 1.5 X ULN ) ; D. Adequate liver function ( Bilirubin &lt; 1.5 X ULN , AST/ALT &lt; 2.5 X ULN ) ECOG Performance status : 01 Cardiac ejection fraction ≥ 50 % measure MUGA 2D echocardiography without clinically significant abnormality Voluntarily participate study , write informed consent patient Past history immunotherapy chemotherapy Past history autologous stem cell transplantation bone marrow transplantation The patient undergone radiation therapy within 4 week write informed consent Patient concurrent malignancy currently cure past history within 5 year ( exclude completely resect stage I early skin cancer ) Pregnant lactate woman , woman childbearing potential employ adequate contraception Other serious illness medical condition inadequate chemotherapy : A. Unstable cardiac disease ( i.e . congestive heart failure , arrhythmia , symptomatic coronary artery disease ) despite treatment , myocardial infarction within 6 month prior study entry ; B . History significant neurological psychiatric disorder include dementia seizure ; Active uncontrolled infection ( viral , bacterial fungal infection ) ; D. Other serious medical illness Known hypersensitivity study drug ingredient Concomitant administration experimental drug investigation , concomitant chemotherapy , hormonal therapy , immunotherapy . Past history usage granulocytecolony stimulate factor Patients known history HIV ( + ) HCV ( + ) . However , HBV ( + ) patient undergo primary prophylaxis eligible . Other serious illness medical condition determine investigator</criteria>
	<gender>Female</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Breast cancer</keyword>
	<keyword>Adjuvant</keyword>
	<keyword>Docetaxel</keyword>
	<keyword>Adriamycin</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Neutropenia</keyword>
	<keyword>Filgrastim</keyword>
	<keyword>Pegfilgrastim</keyword>
</DOC>